Evidence-Based Education on the Potential Impact of a Generic JAK Inhibitor on the Management of Rheumatologic Diseases
Pfizer External Research & Grants (ER&G) (formerly Global Medical Grants & Partnerships) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s ER&G competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Date RFP Issued: Mar 26, 2026
Geographic Scope: United States
Clinical Area: Rheumatology
Link to full RFP: 2026 I&I US JAKi Rheum IME
Application Due Date: May 21, 2026
Specific Area of Interest: This RFP emphasizes the need for educational content that translates data-driven insights into practical clinical decision-making in rheumatologic care.
Proposed initiatives should conduct a thorough analysis of the available data and disseminate the resulting insights through evidence-based educational interventions that address the clinical implications and real-world impact of generic JAK inhibitor use in rheumatologic diseases.
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.